Abstract:Introduction: The study of the pathophysiology study of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. Methods: The humanized APP NL-G-F knock-in mouse line was crossed to the PS19 MAPT P301S , over-expression mouse line to create the dual APPNL-G-F/PS19 MAPTP301S line. The resulting pathologies were characterized by immunochemical methods and PCR. Results: We now report on a double transgenic APP NL-G-F /PS19 MAPT P301S mouse that at 6 months of age exhibits robust A plaque accumulation, intense MAPT pathology, strong inflammation and extensive neurodegeneration. The presence of A pathology potentiated the other major pathologies, including MAPT pathology, inflammation and neurodegeneration. MAPT pathology neither changed levels of amyloid precursor protein nor potentiated A accumulation. Interestingly, study of immunofluorescence in cleared brains indicates that microglial inflammation was generally stronger in the hippocampus, dentate gyrus and entorhinal cortex, which are regions with predominant MAPT pathology. The APP NL-G-F /MAPT P301S mouse model also showed strong accumulation of N 6 -methyladenosine (m 6 A), which was recently shown to be elevated in the AD brain. m 6 A primarily accumulated in neuronal soma, but also co-localized with a subset of astrocytes and microglia. The accumulation of m 6 A corresponded with increases in METTL3 and decreases in ALKBH5, which are enzymes that add or remove m6A from mRNA, respectively. Discussion: Our understanding of the pathophysiology of Alzheimer's disease (AD) has been hampered by lack animal models that recapitulate the major AD pathologies, including extracellular -amyloid (A) deposition, intracellular aggregation of microtubule associated protein tau (MAPT), inflammation and neurodegeneration. The APP NL-G-F /MAPT P301S mouse recapitulates many features of AD pathology beginning at 6 months of aging, and thus represents a useful new mouse model for the field. Graphical . This figure summarizes the pathophysiological changes occurring in the APP NL-G-F /MAPT P301S mouse model. This model has the humanized APP NL-G-F gene as a knocking. The neurons consequently produce abundant Aβ 40/42 which leads to rapid formation of extracellular Aβ plaques. The accumulation of Aβ stimulates inflammation and also feeds back to neurons to enhance MAPT pathology and neurodegeneration. The neurons over-express P301S MAPT, which leads to rapid formation of MAPT pathologies; the amount of pathology is enhanced modestly by the abundant production and aggregation of Aβ. The MAPT aggregation in the neurons stimulate the accumulation of cytoplasmic m 6 A, presumably as part of the translational stress response. Secreted MAPT stimulates microglial inflammation and astrocytosis. All of these factors accelerate neurodegeneration. The inflammation in this model tends to accumulate most in regions with MAPT pathology, particularly the hippocampus, although some reactive microglia are also observed near Aβ plaques.

Altered amyloid-β structure markedly reduces gliosis in the brain of mice harboring the Uppsala APP deletion

Early changes in Abeta levels in the brain of APPswe transgenic mice--implication on synaptic density, alpha7 neuronal nicotinic acetylcholine- and N-methyl-D-aspartate receptor levels

β-amyloid accumulation enhances microtubule associated protein tau pathology in an APPNL-G-F/MAPTP301S mouse model of Alzheimer's disease

Β-Amyloid Accumulation Enhances Microtubule Associated Protein Tau Pathology in an APPNL-G-F/MAPTP301S Mouse Model of Alzheimer’s Disease

Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis

Temporal Characterization of the Amyloidogenic APPswe/PS1dE9;hAPOE4 Mouse Model of Alzheimer's Disease

O1–08–02: Cathepsin B Produces Brain Pyro‐glu‐beta‐amyloid in a Transgenic Alzheimer's Disease Mouse Model

Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission

PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease

Neurodegenerative Changes Associated with β-Amyloid Deposition in the Brains of Mice Carrying Mutant Amyloid Precursor Protein and Mutant Presenilin-1 Transgenes

Amyloid β induces interneuron-specific changes in the hippocampus of APPNL-F mice

A novel mouse model for N-terminal truncated Aβ2-x generation through meprin β overexpression in astrocytes

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia

Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study

Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice

The Accumulation of Aβ Deposits in the Retinas of APPswe/PS1 Transgenic Mice with Retinal Functional Degeneration

Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

The Downregulation of ITGAX Exacerbates Amyloid-β Plaque Deposition in Alzheimer's Disease by Increasing Polarization of M1 Microglia

Characterization of a 3xTg-AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background

Amyloid-Peptide Vaccinations Reduce Beta-Amyloid Plaques but Exacerbate Vascular Deposition and Inflammation in the Retina of Alzheimer'S Transgenic Mice